These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30108715)

  • 1. An agent for optical imaging of TrkC-expressing, breast cancer.
    Kamkaew A; Li F; Li Z; Burgess K
    Medchemcomm; 2017 Oct; 8(10):1946-1952. PubMed ID: 30108715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer.
    Yang Z; Usama SM; Li F; Burgess K; Li Z
    Medchemcomm; 2018 Oct; 9(10):1754-1760. PubMed ID: 30429980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted PDT agent eradicates TrkC expressing tumors via photodynamic therapy (PDT).
    Kue CS; Kamkaew A; Lee HB; Chung LY; Kiew LV; Burgess K
    Mol Pharm; 2015 Jan; 12(1):212-22. PubMed ID: 25487316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling.
    Jin W; Yun C; Kim HS; Kim SJ
    Cancer Res; 2007 Oct; 67(20):9869-77. PubMed ID: 17942918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ hybridization of trkB and trkC receptor mRNA in rat forebrain and association with high-affinity binding of [125I]BDNF, [125I]NT-4/5 and [125I]NT-3.
    Altar CA; Siuciak JA; Wright P; Ip NY; Lindsay RM; Wiegand SJ
    Eur J Neurosci; 1994 Sep; 6(9):1389-405. PubMed ID: 8000564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling.
    Jin W; Yun C; Kwak MK; Kim TA; Kim SJ
    Oncogene; 2007 Dec; 26(55):7684-91. PubMed ID: 17546043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TrkC-Targeted Kinase Inhibitors And PROTACs.
    Zhao B; Burgess K
    Mol Pharm; 2019 Oct; 16(10):4313-4318. PubMed ID: 31512882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Maytansinoid Conjugate Improves Therapeutic Index for Metastatic Breast Cancer Cells.
    Jiang Z; Yang Z; Li F; Li Z; Fishkin N; Burgess K
    Bioconjug Chem; 2018 Sep; 29(9):2920-2926. PubMed ID: 30102524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer.
    Kim MS; Jeong J; Seo J; Kim HS; Kim SJ; Jin W
    Sci Rep; 2016 Sep; 6():33899. PubMed ID: 27654855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TrkC expression predicts favorable clinical outcome in invasive ductal carcinoma of breast independent of NT-3 expression.
    Zhang W; Lin ZC; Zhang TX; Liu S; Liu X; Liu JJ; Niu Y
    Am J Cancer Res; 2014; 4(6):811-23. PubMed ID: 25520870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
    Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
    Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphorylation of TrkB and TrkC and their signal transduction by alpha2-macroglobulin.
    Hu YQ; Koo PH
    J Neurochem; 1998 Jul; 71(1):213-20. PubMed ID: 9648868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hey1- and p53-dependent TrkC proapoptotic activity controls neuroblastoma growth.
    Ménard M; Costechareyre C; Ichim G; Blachier J; Neves D; Jarrosson-Wuilleme L; Depping R; Koster J; Saintigny P; Mehlen P; Tauszig-Delamasure S
    PLoS Biol; 2018 May; 16(5):e2002912. PubMed ID: 29750782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy.
    Kue CS; Kamkaew A; Voon SH; Kiew LV; Chung LY; Burgess K; Lee HB
    Sci Rep; 2016 Nov; 6():37209. PubMed ID: 27853305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TrkC in favorable human neuroblastomas.
    Yamashiro DJ; Nakagawara A; Ikegaki N; Liu XG; Brodeur GM
    Oncogene; 1996 Jan; 12(1):37-41. PubMed ID: 8552397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Small Molecule Probes for Metastatic Melanoma.
    Kamkaew A; Fu N; Cai W; Burgess K
    ACS Med Chem Lett; 2017 Feb; 8(2):179-184. PubMed ID: 28197308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Clinical Significance of Neurotrophin-3 Expression according to MYCN Amplification and TrkC Expression in Neuroblastoma.
    Seo E; Kim JS; Ma YE; Cho HW; Ju HY; Lee SH; Lee JW; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2019 Oct; 34(39):e254. PubMed ID: 31602824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma.
    Sasahira T; Ueda N; Kurihara M; Matsushima S; Ohmori H; Fujii K; Bhawal UK; Yamamoto K; Kirita T; Kuniyasu H
    Hum Pathol; 2013 Jun; 44(6):1098-106. PubMed ID: 23332094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TrkC plays an essential role in breast tumor growth and metastasis.
    Jin W; Kim GM; Kim MS; Lim MH; Yun C; Jeong J; Nam JS; Kim SJ
    Carcinogenesis; 2010 Nov; 31(11):1939-47. PubMed ID: 20802235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.
    Rydén M; Sehgal R; Dominici C; Schilling FH; Ibáñez CF; Kogner P
    Br J Cancer; 1996 Sep; 74(5):773-9. PubMed ID: 8795581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.